Flurbiprofen 0.03% · ophthalmic solution
NSAID
Approved uses
Prevention of intraoperative miosis during cataract surgery
Four drops total, one drop about every half hour starting 2 hours before surgery
Given entirely before the operation: prostaglandin-mediated miosis is prevented, not reversed once it happens
Contraindications
Flurbiprofen sodium ophthalmic solution is contraindicated in individuals who are hypersensitive to any components of the medication.
Flurbiprofen sodium ophthalmic solution 0.03%, 2.5 mL in a plastic bottle with a controlled drop tip
Flurbiprofen is a phenylalkanoic acid NSAID. Its mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins. Prostaglandins appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms.
Warnings & Precautions
- Increased bleeding time: With some NSAIDs there is a potential for increased bleeding time through interference with thrombocyte aggregation, and there have been reports that flurbiprofen sodium ophthalmic solution may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that it be used with caution in surgical patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
- Delayed healing: Topical NSAIDs may slow or delay healing, and concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Cross-sensitivity: There is the potential for cross-sensitivity to acetylsalicylic acid and other NSAIDs, so use caution in individuals who have previously exhibited sensitivities to these drugs.
- Ineffective acetylcholine chloride and carbachol: Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with flurbiprofen sodium ophthalmic solution.
- Contaminated solutions: Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions; avoid allowing the bottle tip to contact the eye or surrounding structures, and use one bottle for each eye with bilateral ocular surgery.
Common Side Effects
Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of flurbiprofen sodium ophthalmic solution. Other adverse reactions reported with the use of flurbiprofen sodium ophthalmic solution include: fibrosis, hyphema, miosis, mydriasis, and ocular hyperemia. Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported.
Pregnancy: Flurbiprofen has been shown to be embryocidal, delay parturition, prolong gestation, reduce weight, and/or slightly retard growth of fetuses when given to rats in daily oral doses of 0.4 mg/kg (approximately 300 times the human daily topical dose) and above. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk; because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established.